Mendus Beheer

Beheer criteriumcontroles 2/4

De CEO Mendus is Erik Manting, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. bezit rechtstreeks 0.46% van de aandelen van het bedrijf, ter waarde € 176.31K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 3.3 jaar.

Belangrijke informatie

Erik Manting

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.7yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

CEO

Erik Manting (53 yo)

3.7yrs

Tenure

Dr. Erik Manting, Ph D., has been the Chief Executive Officer at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Exec...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Erik Manting	Chief Executive Officer	3.7yrs	geen gegevens	0.46% € 176.3k
Alex Karlsson-Parra	Co-Founder & Chief Scientific Officer	16.8yrs	SEK 1.42m	geen gegevens
Lotta Ferm	Chief Financial Officer	3.8yrs	geen gegevens	0.20% € 75.5k
Leopold Bertea	Chief Technology Officer	2.5yrs	geen gegevens	geen gegevens
Jeroen Rovers	Chief Medical Officer	no data	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1YG0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ada Kruisbeek	Chair of Scientific Advisory Board	3.2yrs	geen gegevens	geen gegevens
Sven Andreasson	Independent Chairman	4.6yrs	SEK 325.00k	geen gegevens
Lewis Lanier	Member of Scientific Advisory Board	1.4yrs	geen gegevens	geen gegevens
Hans Preusting	Independent Director	3.5yrs	SEK 330.00k	geen gegevens
Helen Tuvesson	Independent Director	4.6yrs	SEK 355.00k	geen gegevens
Tanja de Gruijl	Member of Scientific Advisory Board	3.2yrs	geen gegevens	geen gegevens
Dharminder Chahal	Independent Director	3.8yrs	SEK 355.00k	0.44% € 166.6k
Inge Svane	Member of Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
Sjoerd van Burg	Member of Scientific Advisory Board	3.2yrs	geen gegevens	geen gegevens
Ted Fjallman	Independent Director	less than a year	SEK 285.00k	geen gegevens

3.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1YG0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Mendus Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Mendus AB (publ), Annual General Meeting, May 09, 2025

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB (publ), Annual General Meeting, May 17, 2024

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Recent updates

New major risk - Revenue size

Mendus AB (publ), Annual General Meeting, May 09, 2025

Mendus AB (publ) to Report Fiscal Year 2024 Final Results on Apr 18, 2025

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Now 24% overvalued

Forecast to breakeven in 2025

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

New major risk - Financial position

Mendus AB (Publ) Announces Clinical Pipeline Update

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Mendus AB (publ), Annual General Meeting, May 17, 2024

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Forecast to breakeven in 2023

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought €241k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

New 90-day low: €0.67

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

Independent Chairman Michael S. Oredsson has left the company

Immunicum AB (Publ) Announces Executive Changes

Immunicum AB (publ) Approves Election of New Board Members

Immunicum AB (publ) Announces Transitions in Board of Directors

New 90-day low: €0.70

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Immunicum AB (publ) Announces Changes to the Nomination Committee

Immunicum AB (publ) (OM:IMMU) completed the acquisition of DCPrime B.V. from Van Herk Investments B.V. and others.

Immunicum AB (Publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial

Immunicum AB (publ) to Report First Half, 2021 Results on Aug 26, 2021

Immunicum AB (publ) (OM:IMMU) entered into a share purchase agreement to acquire DCPrime B.V. from Van Herk Investments B.V. and others for €58.8 million.

Immunicum AB (Publ) Announces Appointment of Hans Derninger to the Nomination Committee